Journal Article
Research Support, Non-U.S. Gov't
Add like
Add dislike
Add to saved papers

Prognostic significance of CD44 molecule in renal cell carcinoma.

AIM: To analyze the expression and the prognostic value of CD44s and variant v5 and v6 isoforms in a large series of conventional renal cell carcinomas.

METHODS: The expression of CD44 isoforms was immunohistochemically evaluated in 173 conventional renal cell carcinomas, and was compared with the usual clinicopathological parameters such as tumor size, histological grade, pathological stage, and Ki-67 proliferative index. The relationship of the CD44 expression to the cancer-specific survival was evaluated by log rank test.

RESULTS: While normal renal tissue was negative for CD44s protein, it was upregulated in 70 (40.5%) out of 173 carcinomas, and its expression significantly correlated with histological grade (p<0.001), pathological stage (p=0.023), and Ki-67 proliferative index (p<0.001). Moreover, the expression of CD44s protein was an adverse prognostic parameter in univariate survival analysis for patients with tumors expressing high levels of CD44s protein (p=0.003). CD44v5 and v6 isoforms were expressed in 11 (6.4%) and 28 (16.2%) tumors, respectively. Their expression was significantly higher in tumors with higher histological grade (p=0.001 and p=0.001, respectively). Also, the expression of v6 isoform was higher in tumors with high proliferation activity (p=0.001).

CONCLUSION: CD44s molecule may play a role in the progression of conventional renal cell carcinoma, and may be used in the evaluation of disease outcome.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app